Tocqueville Asset Management L.P. boosted its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 2.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 90,630 shares of the exchange traded fund’s stock after purchasing an additional 2,535 shares during the quarter. Tocqueville Asset Management L.P.’s holdings in SPDR S&P Biotech ETF were worth $8,689,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in XBI. WealthPLAN Partners LLC raised its stake in SPDR S&P Biotech ETF by 4.9% during the 2nd quarter. WealthPLAN Partners LLC now owns 12,049 shares of the exchange traded fund’s stock valued at $1,147,000 after acquiring an additional 560 shares in the last quarter. BB&T Securities LLC raised its stake in SPDR S&P Biotech ETF by 5.8% during the 2nd quarter. BB&T Securities LLC now owns 11,533 shares of the exchange traded fund’s stock valued at $1,097,000 after acquiring an additional 635 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in SPDR S&P Biotech ETF by 14.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,035 shares of the exchange traded fund’s stock valued at $483,000 after acquiring an additional 635 shares in the last quarter. Cypress Capital Management LLC WY raised its stake in SPDR S&P Biotech ETF by 51.8% during the 2nd quarter. Cypress Capital Management LLC WY now owns 2,065 shares of the exchange traded fund’s stock valued at $197,000 after acquiring an additional 705 shares in the last quarter. Finally, Boothe Investment Group Inc. raised its stake in SPDR S&P Biotech ETF by 2.5% during the 3rd quarter. Boothe Investment Group Inc. now owns 29,111 shares of the exchange traded fund’s stock valued at $2,791,000 after acquiring an additional 708 shares in the last quarter.

Shares of SPDR S&P Biotech ETF stock opened at $78.19 on Friday. SPDR S&P Biotech ETF has a 1-year low of $73.97 and a 1-year high of $101.55.

COPYRIGHT VIOLATION NOTICE: “Tocqueville Asset Management L.P. Has $8.69 Million Position in SPDR S&P Biotech ETF (XBI)” was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.watchlistnews.com/tocqueville-asset-management-l-p-has-8-69-million-position-in-spdr-sp-biotech-etf-xbi/2670957.html.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Recommended Story: What is Net Asset Value (NAV)?

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.